Peripheral vascular disease: Diagnosis and treatment

American Family Physician

Volumn 73, Issue 11, 2006, Pages 1971-1976

  Sontheimer, Daniel L ^a,b  

^a Family Practice Residency   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; PENTOXIFYLLINE; PLASMINOGEN ACTIVATOR; RAMIPRIL; TICLOPIDINE; UROKINASE; WARFARIN;

ANGIOPLASTY; ANKLE BRACHIAL INDEX; ARTERY OCCLUSION; ARTICLE; BRACHIAL ANGIOGRAPHY; BYPASS SURGERY; CLINICAL TRIAL; COMPARTMENT SYNDROME; DIABETES MELLITUS; DIET; ECHOGRAPHY; EXERCISE; GRAFT PATENCY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERMITTENT CLAUDICATION; LIMB ISCHEMIA; META ANALYSIS; NERVE ROOT COMPRESSION; NUCLEAR MAGNETIC RESONANCE; PERIPHERAL VASCULAR DISEASE; POPLITEAL CYST; POSTOPERATIVE COMPLICATION; PRIMARY PREVENTION; PROGNOSIS; QUESTIONNAIRE; SMOKING CESSATION; STENT; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION; VERTEBRAL CANAL STENOSIS;

CONSTRICTION, PATHOLOGIC; DIAGNOSIS, DIFFERENTIAL; HUMANS; INTERMITTENT CLAUDICATION; PERIPHERAL VASCULAR DISEASES; PHYSICAL EXAMINATION; SENSITIVITY AND SPECIFICITY;

EID: 33744958904     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 1985;33:13-8.
2. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-24.
3. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation 1997;96:44-9.
4. Agency for Healthcare Research and Quality. Screening for peripheral arterial disease: a brief evidence update for the U.S. Preventive Services Task Force. Rockville, Md., Agency for Healthcare Research and Quality, 2005. Accessed December 20, 2005, at: http://www.ahrq.gov/clinic/uspstf05/pad/padup. htm.
5. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000;31(1 pt 2):S1-S296.
6. Leng GC, Fowkes FG. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol 1992;45:1101-9.
7. O'Hare AM, Glidden DV, Fox CS, Hsu CY. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. Circulation 2004;109:320-3.
8. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.
9. Stoffers HE, Kester AD, Kaiser V, Rinkens P, Knottnerus JA. Diagnostic value of signs and symptoms associated with peripheral arterial occlusive disease seen in general practice: a multivariable approach. Med Decis Making 1997;17:61-70.
10. McGee SR, Boyko EJ. Physical examination and chronic lower-extremity ischemia: a critical review. Arch Intern Med 1998;158:1357-64.
11. Christensen JH, Freundlich M, Jacobsen BA, Falstie-Jensen N. Clinical relevance of pedal pulse palpation in patients suspected of peripheral arterial insufficiency. J Intern Med 1989;226:95-9.
12. TransAtlantic Intersociety Consensus (TASC). Management of peripheral arterial disease (PAD). Eur J Vasc Endovasc Surg 2000;19(suppl A):S1-250.
13. Burns P, Gough S, Bradbury AW. Management of peripheral arterial disease in primary care. BMJ 2003;326:584-8.
14. Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Semin Vasc Surg 1999;12:123-37.
15. Jonason T, Bergström R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 1987;221:253-60.
16. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev 2005;(1):CD000990.
17. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [Published correction appears in BMJ 2002;324:141]. BMJ 2002;324:71-86.
18. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
19. Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998;27:267-75.
20. Dawson DL, Cutler BS, Hiatt WR, Hobson RW II, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000;109:523-30.
21. Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999;159:2041-50.
22. Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis. Cochrane Database Syst Rev 2000;(2):CD000123.
23. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003;114:359-64.
24. Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003;107:753-6.
25. American Diabetes Association. Standards of medical care for patients with diabetes mellitus [Published correction appears in Diabetes Care 2003;26:972]. Diabetes Care 2003;26(suppl 1):S33-50.
26. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [Published correction appears in N Engl J Med 2000;342:1376]. The Heart outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
27. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy [Published correction appears in Lancet 2000;356:860]. Heart outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9.
28. Cosmi B, Conti E, Coccheri S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev 2005;(1):CD001999.
29. Becquemin JP. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine après Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie. N Engl J Med 1997;337:1726-31.
30. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996;25:1172-81.